About FDA

Division of Oncology Products 2 (DOP2)

Director: Patricia Keegan, M.D.
Deputy Director: Joseph Gootenberg, M.D.
Associate Deputy Director: Martha Donoghue (Acting)
Deputy Director of Safety: Jeffrey Summers, M.D.

SRPM: Karen Hennessy

Chief, Project Management Staff: Melanie Pierce
Chief, Project Management Staff: Monica Hughes

The Division of Oncology Products 2 (DOP2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas:

  1. Gastrointestinal Cancers
  2. Lung/Head & Neck Cancers
  3. Neuro-oncology/Rare cancers/Pediatric Solid Tumor
  4. Melanoma/Sarcoma

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Oncology Products 2 (DOP2)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Phone: (301) 796-2320
Fax: (301) 796-9849

Page Last Updated: 02/28/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English